Chief Medical Officer Proteon Therapeutics
Gastroenterology
Dr. Steven K. Burke, MD
|
|
Give Review
Doctor Steven K. Burke, MD is an expert in the field of Gastroenterology. He went to medical school at Weill Cornell Medical College of Cornell University. Weill Cornell Medical College of Cornell University is ranked 18 in research and 49 in primary care medicine Doctor Steven K. Burke, MD is also published. He has 46 publications published. The lastest publication: "A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism ...' Steven Burke accepts Medicare payments and is listed with Medicare.gov.
Publications
- Effects of recombinant human type I pancreatic elastase on human atherosclerotic arteries.
- Application of human type I pancreatic elastase (PRT-201) to the venous anastomosis of arteriovenous grafts in patients with chronic kidney disease.
- A multi-center, dose-escalation study of human type I pancreatic elastase (PRT-201) administered after arteriovenous fistula creation.
- Sevelamer restores bone volume and improves bone microarchitecture and strength in aged ovariectomized rats.
- Phosphate is a uremic toxin.
- Results of a randomized crossover study comparing once-daily and thrice-daily sevelamer dosing.
- Novel dosage forms and regimens for sevelamer-based phosphate binders.
- Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis.
- Arterial calcification in chronic kidney disease.
- Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia.
- Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats.
- Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients.
- The effects of sevelamer hydrochloride and calcium carbonate on kidney calcification in uremic rats.
- Effect of colesevelam on lovastatin pharmacokinetics.
- Absorption of colesevelam hydrochloride in healthy volunteers.
- Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease?
- Bacteremia after endoscopic band ligation of esophageal varices.
- Activation of functionally distinct subsets of CD4+ T lymphocytes.
- Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia.
- Renagel: reducing serum phosphorus in haemodialysis patients.
- Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects.
- Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively.
- Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hyperchol...
- Sevelamer hydrochloride (Renagel), a non-calcaemic phosphate binder, arrests parathyroid gland hyperplasia in rats with progressive chronic renal insufficiency.
- Hyperparathyroidism and dialysis vintage.
- Effects of colesevelam HC1 on sterol and bile acid excretion in patients with type IIa hypercholesterolemia.
- A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients.
- Renal mineral handling in normal rats treated with sevelamer hydrochloride (Renagel), a noncalcemic phosphate binder.
- Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients.
- Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients.
- Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent.
- Sevelamer hydrochloride (Renagel), a phosphate-binding polymer, does not alter the pharmacokinetics of two commonly used antihypertensives in healthy volunteers.
- Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients.
- A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism ...
- Sevelamer with and without calcium and vitamin D: observations from a long-term open-label clinical trial.
- RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group.
- Effect of RenaGel, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal diseas...
- RenaGel, a novel calcium- and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers.
- Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure.
- Sevelamer, a phosphate-binding polymer, is a non-absorbed compound.
- Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients.
- Sevelamer hydrochloride, a phosphate binder, protects against deterioration of renal function in rats with progressive chronic renal insufficiency.
- The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients.
- Determinants of progressive vascular calcification in haemodialysis patients.
- The ability of serum from alpha 1-antitrypsin-deficient patients to inhibit PRT-201, a recombinant human type I pancreatic elastase.
Schools
Weill Cornell Medical College
Brigham and Women39s Hospital
Brigham and Womens Hospital
Doctors Specialties
- Gastroenterology
Accepted Insurances
- Medicare MCR
Education
-
Brigham and Women's Hospital -
Weill Cornell Medical College of Cornell University
Helpful Reviews
Similar Doctors
|
|
Dr. Bruce Becker, MD |
|
|
Dr. Stephen J. Brand, MD |